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Loss of protein quality control by the ubiquitin-proteasome system (UPS) during aging
is one of the processes putatively contributing to cellular stress and Alzheimer’s
disease (AD) pathogenesis. Recently, pooled GenomeWide Association Studies (GWAS),
pathway analysis and proteomics identified protein ubiquitination as one of the key
modulators of AD. Mutations in ubiquitin B mRNA that result in UBB+1 dose-dependently
cause an impaired UPS, subsequent accumulation of UBB+1 and most probably
depositions of other aberrant proteins present in plaques and neurofibrillary tangles. We
used specific immunohistochemical probes for a comprehensive topographic mapping
of the UBB+1 distribution in the brains of transgenic mouse line 3413 overexpressing
UBB+1. We also mapped the expression of UBB+1 in brain areas of AD patients selected
based upon the distribution of UBB+1 in line 3413. Therefore, we focused on the olfactory
bulb, basal ganglia, nucleus basalis of Meynert, inferior colliculus and raphe nuclei.
UBB+1 distribution was compared with established probes for pre-tangles and tangles
and Aβ plaques. UBB+1 distribution found in line 3413 is partly mirrored in the AD brain.
Specifically, nuclei with substantial accumulations of tangle-bearing neurons, such as the
nucleus basalis of Meynert and raphe nuclei also present high densities of UBB+1 positive
tangles. Line 3413 is useful for studying the contribution of proteasomal dysfunction
in AD. The findings are consistent with evidence that areas outside the forebrain are
also affected in AD. Line 3413 may also be predictive for other conformational diseases,
including related tauopathies and polyglutamine diseases, in which UBB+1 accumulates
in their cellular hallmarks.
Keywords: frameshift mutation, ubiquitin B+1, olfactory bulb, basal ganglia, nucleus basalis of Meynert, inferior
colliculus, raphe nuclei, RNA
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Introduction
Alzheimer’s disease (AD) is a multifactorial disease and the most
prevalent form of dementia. Currently, it is estimated to affect at
least 20 million people worldwide and the prevalence is expected
to triple within the next 40 years (Barnes and Yaffe, 2011). AD
neuropathology is characterized by two cellular hallmarks: the
accumulation of extracellular plaques mainly composed of amy-
loid β (Aβ) and of intracellular hyperphosphorylated tau in neu-
rofibrillary tangles (NFTs) (Selkoe, 2001). In autosomal dominant
AD cases (accounting for<3%) (Van Leeuwen et al., 2000), muta-
tions in three different genes have been identified: the amyloid
precursor protein (APP) and the presenilin 1 (PS1) and 2 (PS2)
genes. Pathogenic mutations in these genes contribute to aber-
rations of the γ-secretase complex, which leads to an increased
production of toxic Aβ42 (Jankowsky et al., 2004). In the tau
gene of AD patients no mutations have been reported so far. The
major risk factor for developing sporadic AD is aging whereas
the ε4 polymorphism of the apolipoprotein E gene (APOE) is the
most prominent genetic risk factor (Corder et al., 1993). Other
medium-risk factors such as a missense mutation in the gene
encoding the triggering receptor expressed on myeloid cells 2
(TREM2) (Jonsson et al., 2013) and nine low risk factors from
Genome Wide Association Studies (GWAS) were reported to
contribute to AD (Holton et al., 2013). Recently, pooled GWAS
studies and pathway analysis also identified protein ubiquitina-
tion as one of the key modulators of AD (International Genomics
of Alzheimer’s Disease Consortium (IGAP), 2015). In this study
they implicate that the immune response, regulation of endocy-
tosis, cholesterol transport, and protein ubiquitination represent
prime targets for AD therapeutics. In addition, a brain site spe-
cific strategy was used to compare the proteomes of prefrontal
cortex, hippocampus and cerebellum in brains of AD patients
(Manavalan et al., 2013). An Ingenuity Pathway Analysis demon-
strated 31 proteins were significantly altered and that these pro-
teins had a strong interaction with the ubiquitin C (UBC) sig-
naling pointing to a dysfunctional ubiquitin proteasome system
(UPS) as a causative factor in AD (Manavalan et al., 2013).
Neuronal development and synaptic plasticity are part of pro-
cesses that involve metabolism of 5–8% of brain proteins each
day (Dennissen et al., 2012). This turnover requires an efficient
protein quality control (PQC) for which the UPS and autophagy
are mainly responsible. We discovered that the transcription of
Abbreviations: Aβ, amyloid β protein; ABC, avidin-biotin complex; AD,
Alzheimer’s disease; APOE, apolipoprotein E; APP, amyloid precursor protein;
CAD, central auditory dysfunction; CaMKIIα, Calmodulin kinase II alpha; D,
density; DAB, diaminobenzidine; DAergic, dopaminergic; DUB, deubiquitinat-
ing enzyme; FENIB, familial encephalopathy with neuroserpin inclusion bodies;
ERAD, ER-associated degradation; GWAS, Genome Wide Association Studies;
HD, Huntington’s disease; HTh, hypothalamus; I, intensity; ir, immunoreactivity
; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; NA, nora-
drenaline; NFT, neurofibrillary tangle; NMDA, N-methyl-D-aspartate; NT, neu-
ropil threads; PBS, phosphate-buffered saline ; PHF, paired helical filament; PQC,
protein quality control; PS1, presenilin 1; PS2, presenilin 2; RT, room tempera-
ture; SPECT, single-photon emission computed tomography; TBS, Tris-buffered
saline ; tg, transgenic; TREM2, triggering receptor expressed on myeloid cells 2;
UBB, ubiquitin B; UBB+1, ubiquitin B+1; UBB+1I, intensity of UBB+1 immunore-
activity; UBB+1D, density of UBB+1 immunoreacitivity; UBC, ubiquitin C; UPS,
ubiquitin-proteasome system; 5-HT, serotonin.
the ubiquitin B (UBB) gene can result in accumulation of mutant
ubiquitin B+1 (UBB+1) in the cellular hallmarks (plaques and
tangles) of sporadic and autosomal dominant AD cases, suggest-
ing a pathological function (Van Leeuwen et al., 1998, 2006).
Similarly, other tauopathies, as well as several polyglutamine dis-
eases (e.g., Huntington’s diseases (HD)) are characterized by the
accumulation of UBB+1 in the respective hallmarks. By contrast,
UBB+1 appears not to be involved in synucleinopathies (Fischer
et al., 2003; De Pril et al., 2004). UBB+1 compromises PQC by
inhibiting the UPS dose-dependently (Dennissen et al., 2012) via
inhibition of deubiquitinating enzymes (DUB) (Krutauz et al.,
2014).
In vivo studies performed in a transgenic (tg) line (#3413)
overexpressing human UBB+1, specifically in neurons postna-
tally, showed increased levels of ubiquitinated proteins in the
forebrain (e.g., cerebral cortex, hippocampus, dentate gyrus,
amygdala, and striatum). These tg mice show deficits in contex-
tual memory, a decrease in proteasome activity and proteomic
changes reminiscent of AD (Fischer et al., 2009). In addition, a
comprehensive phenotypic screen of line 3413 revealed a respi-
ratory phenotype (Irmler et al., 2012). Changes in spontaneous
breathing patterns and an altered hypoxic response, suggested
a central dysfunction of respiratory regulation. In keeping with
this, expression of UBB+1 was found in the nucleus of the trac-
tus solitarius (Sol) and the parabrachial nuclei, brainstem nuclei
involved in respiratory control. These data suggest that respi-
ratory centers in the brainstem are sensitive to long-term UPS
inhibition via the expression of the UBB+1 protein. Most inter-
estingly, UBB+1 immunoreactivity in AD patients was seen in
similar areas as in the tg mice, suggesting a possible functional
link between UBB+1 expression in brainstem areas and the res-
piratory and swallowing dysfunctions that are often seen in AD
patients (Irmler et al., 2012). Moreover, in early stages of AD, it
has been noted that increased cardiorespiratory (CR) fitness in
early-stage AD is associated with reduced brain atrophy as com-
pared with non-demented individuals (Burns et al., 2008). It was
also shown that declining CR fitness over 2 years was associated
with brain atrophy, especially in the parahippocampus in AD
(Vidoni et al., 2012). Dysphagia is also an issue in Parkinson’s dis-
ease (PD) caused by synucleinopathology in the glossopharyngeal
nucleus (Braak et al., 2003; Cereda et al., 2014), starts initially in
the dorsal motor nucleus of the vagus nerve (Braak et al., 2003)
but it is UBB+1 negative.
Previous studies have concentrated mainly on parts of the
forebrain and the brainstem; however, information about UBB+1
accumulation in other brain areas of these tg mice and the possi-
ble functional consequences of UBB+1 expression has been lack-
ing. The pattern of UBB+1 expression and expression levels in
the tg mice are largely dictated by copy numbers and CamKIIα
promotor elements used to drive expression, therefore the results
of the tg mice must not be overestimated (Fischer et al., 2009).
The aim of the present study is to provide a comprehensive topo-
graphic mapping of UBB+1 in the brains of the tg mouse line
3413. Due to the extensive UBB+1 expression in certain mouse
brain areas, a next step was to compare this distribution with
the distribution of UBB+1 and established markers of AD in
the human brain. This approach identified two immunoreactive
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brainstem areas that show a similar immunoreactivity in AD and
could be linked to respiratory dysfunction (Irmler et al., 2012).
As we detected additional high intensities of UBB+1 immunore-
activity, especially in five other brain areas in line 3413, we focus
here on these brain areas known to be affected in AD, namely
the olfactory bulb (OB), basal ganglia, nucleus basalis of Meynert
(NBM), raphe nuclei and inferior colliculus (IC) and discuss their
potential relevance for AD research.
Materials and Methods
Animals
In the present study, UBB+1 tg male mice (line 3413,
008833C57Bl/6.Tg(CaMKIIα-UBB) 3413, Jackson #008833) (n=
14; eight 3-month-old mice, two 7-month-old mice, and four
15-month-old mice) expressing human UBB+1 in the postnatal
brain on a pure C57BL/6 background were used (Fischer et al.,
2009). UBB+1 cDNA is encoded by the first ubiquitin upstream
open reading frame and a murine calmodulin kinase II alpha
(CaMKIIα) promoter was used to regulate the UBB+1 expression
in the tg mice (Van Leeuwen et al., 1998). Non-transgenic litter-
mates were used as controls (n = 9). To ensure comparability
among individuals, mice were kept under standard animal hous-
ing conditions: a 12/12 h light- dark cycle with food and acidified
water ad libitum in specific pathogen free conditions.
All animals used in the present study were males and
were sacrificed at either 3, 7 and 15 months of age. All ani-
mal experiments were performed conforming to national ani-
mal welfare law and under guidance of the animal welfare
committees of the Royal Netherlands Academy of Arts and
Sciences and of Maastricht University (Dier Experimenten Com-
missie (DEC/Animal Experiments Commission) protocol nr.
2008-069).
Immunohistochemistry
Mice were deeply anesthetized with sodium pentobarbital and
were perfused transcardially with Tyrode solution (2.68mM
KCl, 0.245mM MgCl2.6H2O, 136mM NaCl, 0.289mM
NaH2PO4.H2O, 5mM glucose, 12mMNaHCO3;pH 7.4) aerated
with carbogen followed by 0,1M phosphate buffer containing
4% paraformaldehyde (pH 7.4). Brains were removed and
placed in fixative overnight on a rocking table at 4◦C. Sub-
sequently, they were stored in a 1% sodium azide (NaN3)
phosphate-buffered saline (PBS) solution in a cold room at 4◦C
until further processing. Brains were embedded in gelatin and
sectioned on a Vibratome (Leica VT 1200S, Wetzlar, Germany)
into 50µm coronal or sagittal free-floating sections. Tissue
sections were stained overnight at 4◦C (first 1 h at room tem-
perature (RT)) with a primary polyclonal rabbit anti-UBB+1
antibody (Ubi3 16/09/97, final dilution 1:1000), recognizing
the C-terminal extension of the UBB+1 protein (Fischer et al.,
2003). The sections were incubated with a biotinylated donkey
anti-rabbit antibody (1:400) (Jackson Laboratories) followed
by avidin-biotin-peroxidase (ABC,1:400, Vector), both 1 h at
RT. The staining was visualized with 3,3′-diaminobenzidine
tetrahydrochloride (DAB) solution intensified by 0.2 % nickel
ammonium sulfate (pH7.6). The sections were mounted on
gelatin-coated glass slides, air dried, dehydrated, and cover-
slipped using Pertex (Histolab). As controls for Ubi3 specificity,
Ubi3 antiserum adsorbed with 6His tag UBB+1 as well as the
pre-immune control serum were used.
Human postmortem tissue (OB, basal ganglia, NBM, IC,
and raphe nuclei) from AD patients and non-demented con-
trols was obtained from the Radboud University Medical Cen-
ter (Department of Pathology, Nijmegen, The Netherlands,
Table 1). Anonymised human material from AD-patients and
non-demented control patients was used according Dutch law
and local guidelines. The number of available human tissue mate-
rial of the patients is different for each of the focused brain
areas. The tissues were fixed in 4% buffered paraformaldehyde
for at least 3 weeks. Part of the human OB tissue specimens
were cryoprotected in 10% sucrose solution (0.1M phosphate
buffer, pH 7.6, at 4◦C) followed by at least 72 h incubation in 20%
sucrose solution. Subsequently, this tissue was frozen and stored
at −80◦C. Coronal sections of 8µm thickness were mounted
on gelatin-coated glass slides and stored at −80◦C until further
processing. The other OB tissue specimens with olfactory cor-
tex added were dehydrated, embedded in paraffin and cut in the
sagittal plane, producing serial sections of 8µm thickness each.
Tissue of the basal ganglia, NBM, IC, and raphe nuclei were
fixed in 4% buffered paraformaldehyde for 1 month after which
the unembedded tissue was cut on a Vibratome in 50µm thick
sections and stored at 4◦C in PBS with 1% NaN3until further
processing. Basal ganglia were cut in the coronal plane, whereas
brainstem (IC and raphe nuclei) was cut perpendicular to the
long axis of the spinal cord, to take into account the flexures of
the human neuraxis.
To perform immunohistochemistry, the frozen sections and
the paraffin-embedded sections (after deparaffination) were incu-
bated for 30min in 100% formic acid followed by rinsing in dis-
tilled water (30min) and in Tris-buffered saline (TBS) (30min)
and subsequently incubated overnight at 4◦C (first 1 h at RT) with
antibodies against misfolded tau (monoclonal MC1, 1:100, Dr. P.
Davies, New York) (Petry et al., 2014), phosphorylated tau ser-
ine 202 (monoclonal CP13, 1:100 Dr. P. Davies, New York)(Petry
et al., 2014), amyloid β (monoclonal 6F3D,1:100, Dako) and
UBB+1 (polyclonal Ubi2A, 180398, 1:400 or polyclonal Ubi2+1
140994, 1;400). All dilutions were in Sumi buffer (0.05M Tris
with 0.9% NaCl, 0.25M gelatin and 0.5% Triton X-100, pH 7.4)
(Fischer et al., 2003; Van Leeuwen et al., 2006). Next, sections
were incubated with secondary donkey anti-mouse or donkey
anti-rabbit antibodies, both biotinylated (1:400, Jackson Labora-
tories) andABC (1:400, Vector), both 1 h at RT and finally stained
with DAB, dehydrated and coverslipped as described above.
Free-floating Vibratome sections were pretreated with 100%
formic acid for the 6F3D antibody for 30min and then rinsed
in distilled water (30min) and TBS (10min). Subsequently, all
sections were treated with graded series of methanol (20, 40, 60,
80% (10min) and 100% (30min), and back to 20%methanol with
0.3% H2O2. Rinsing was performed for 30min in TBS followed
by 30min in Sumi buffer. Sections were then incubated with a
primary antibody (1 h at RT followed by 36 h incubation at 4◦C in
a humid chamber), biotinylated secondary antibodies (2 h at RT),
ABC (2 h at RT), and DAB as described above. All sections were
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TABLE 1 | Clinico-pathological information of non-demented controls and AD patients.
Case* Age Sex Braak Amyloida Brain Cause of Olfactory Basal Inferior Raphe Brainstem**
(years) (f/m) stagea Weight (g) dealth bulb gangliav Colliculusv Nucleiv
NTSv PBNv
1 52 m 0 0 1424 Cardiac infarction +c − − − + +
2 59 f 0 0 1523 Cardiac infarction lung
oedema
− + + + + +
3 73 m 0 0 1474 Unknown +p + + + − −
4 87 m 3 Sparse 1245 Cardiorespiratory failure with
cardiac decompensation,
signs of pneumonia and
sepsis
+
c
+ + + + +
5 64 m 5 Frequent 1123 Cardiorespiratory insufficiency +p + + + − −
6 66 m 5 Frequent 1360 Unknown +p + + + − −
7 68 m 5 Frequent 1312 Subcortical bleeding − + + + + +
8 90 f 5 Frequent 1118 Asystolic +p + + + − −
9 64 f 6 Frequent 1250 Cachexia, dehydration +c − − − + +
10 84 f 6 Frequent 1090 Uraemia, dehydration,
respiratory tract infection
+c − − − + +
a, based upon examination of temporal cortex and hippocampus.
p, paraffin-embedded sections of the olfactory bulb and olfactory cortex (8µm).
c, cryostat sectioned olfactory bulb and olfactory cortex tissue (10µm).
v, Vibratome sectioned brain tissue (50µm).
* All patients had a postmortem delay between 24 and 48 h and a fixation time of at least 3 months.
**Brainstem data reported in Irmler et al. (2012).
−, no tissue available.
mounted on gelatin-coated glass slides, air dried, dehydrated and
coverslipped with DPX (Klinipath). As controls for Ubi2+1 and
Ubi2A specificity, Ubi2+1 and Ubi2A antiserum adsorbed with
6His tag UBB+1 as well as the pre-immune control serum were
used (Van Leeuwen et al., 1998; Fischer et al., 2003).
Microscopy
Brain sections of 3413 tg and control mice were analyzed semi-
quantitatively using an atlas (Franklin and Paxinos, 2007) and
light microscopy, by focusing on intensity (I) of individual neu-
ron staining and density (D) of relative numbers of stained neu-
rons showing UBB+1 immunoreactivity (ir) in a specific brain
nucleus. Intensity is defined as the stain quality in a specific
brain region while density is defined as the number of UBB+1
immunoreactive cells in this region. Scoring was assessed inde-
pendently by two observers: - no UBB+1 ir, + a low I or D of
UBB+1-ir cells, ++ a moderate I or D of UBB+1-ir cells, + + +
a high I or D of UBB+1-ir cells, and + + ++ a very high I or D
of UBB+1-ir cells. The mean I and D per brain nuclei were deter-
mined semi-quantitatively for final results. Based on these scores,
five areas with a high expression of UBB+1 were selected for the
analysis of the human tissue.
For the human sections a similar semi-quantitative approach
was applied for the light-microscopic analysis. Layers of the OB
were defined following indications provided in (Mai and Paxinos,
2012).
Subdivisions of basal ganglia (Mai et al., 2008) and brainstem
nuclei (Haines, 2011) were identified, using atlases, based upon
their topographical position. Figure S1 illustrates micrographs of
sections used for the analysis, taken at the levels of basal gan-
glia and mesencephalon showing corresponding subdivisions in
nuclei and whitematter regions. The presence of AD-related neu-
ropathology was estimated semi-quantitatively as − (negative),
+ (low),++ (moderate), and+++ (high) based on densities of
NFTs, plaques and positive neuronal cells. In addition, qualitative
descriptions were made on the distribution of neuropathology
and themorphological features within the structures. Specifically,
a classification of immunoreactive substrates was made upon the
categorization proposed by Duyckaerts et al. (2009). Amyloid
deposits were identified as neuritic plaques when they presented
a tau-positive corona of dystrophic neurites or as plaques when
such neuritic components were absent. Tau-immunoreactivity
was further identified as neuropil threads (NTs) when stained
substrates had the form of small, tortuous processes and as NFTs
when immunoreactivity also present in neuronal somata. Pho-
tographs weremade using a dotSlide BX51microscope (Olympus,
Japan).
Results
The main goals of the present study were to describe the distri-
bution of UBB+1 in the brain of a UBB+1 tg mice model com-
pared to control mice and to compare the distribution to that in
homologous human brain areas. One can observe high or intense
staining of individual neurons and a low density of intensely
stained neurons and vice versa. No differences in immunoreac-
tivity were found among 3-, 7-, and 15-month-old 3413 tg mice
(Table 2, Table S2) and UBB+1 was absent in all brain regions
of the control mice (Van Tijn et al., 2011). The incubation of tg
mouse brain tissue with 6His tag UBB+1 and the pre-immune
control serum resulted in an absence of immunopositive staining
(Irmler et al., 2012). Relative UBB+1 immunoreactivity scores for
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TABLE 2 | UBB+1 immunoreactivity in the cerebral cortex, hippocampus,
dentate gyrus, striatum, amygdala, nucleus parabrachialis, locus
coeruleus, nucleus of the tractus solitarius, olfactory area, basal ganglia,
nucleus basalis of Meynert, auditory area and in the raphe nuclei of 3413
tg mice.
Brain nuclei 3413 UBB+1I 3413 UBB+1 D
CEREBRAL CORTEX
Apir ++ ++
Cent +++ +++
Cg1 ++ ++
Cg2 ++ ++
Cortical L1 − −
Cortical L2 ++ +++
Cortical L3 + +++
Cortical L4 + +++
Cortical L5a + +
Cortical L5b ++ ++
Cortical L6 + ++
CxA + ++
Den ++ ++
DP + ++
Ect ++ +++
FrA ++ ++
IL + +
LO ++ ++
M2 ++ ++
Pir ++ ++
PrL + ++
RSD ++ ++
RSGa +++ ++
RSGb +++ ++
RSGc +++ ++
V1 +++ +++
V2MM ++ ++
V2ML − −
Ven ++ ++
VO ++ ++
HIPPOCAMPUS
CA1 +++ ++++
CA2 +++ ++++
CA3 +++ +++
FC ++ +++
Ig ++ +++
Lmol − −
Mol − −
PaS ++ ++
PrS ++ ++
Py +++ ++++
Rad − −
Sb ++ ++
Shi ++ +++
Slu +++ ++++
(Continued)
TABLE 2 | Continued
Brain nuclei 3413 UBB+1I 3413 UBB+1 D
DENTATE GYRUS
PoDG ++ ++
GrDG +++ ++++
AMYGDALA NUCLEI
AAD + +
AAV + +
Aco − −
Ahi + ++
AhiAL + ++
AhiPM ++ ++
Astr ++ ++
BLA + ++
BLP ++ ++
BLV + ++
BMA + ++
BMP + ++
CeC ++ ++
CeL ++ ++
CeM + ++
CeMAD + ++
CeMAV + ++
CeMPV + ++
I ++ +
IM + ++
La ++ ++
LaDL ++ ++
LaVL ++ ++
LaVM + +
MeA + ++
MeAD ++ ++
MeAV ++ ++
MePD ++ ++
MePV + ++
PLCo ++ ++
PMCo + ++
SLEA + +
SLEAC + +
SLEAM + ++
NUCLEUS PARABRACHIALIS
LPB +++ +++
LPBC +++ ++
LPBD ++++ +++
LPBE ++++ +++
LPBI ++ ++
LPBV ++ ++
MPB +++ ++
MPBE ++ ++
PBW + ++
LOCUS COERULEUS
LC + ++
(Continued)
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TABLE 2 | Continued
Brain nuclei 3413 UBB+1I 3413 UBB+1 D
NUCLEUS TRACTUS SOLITARIUS/AREA POSTREMA/DORSAL MOTOR
NUCLEUS OF THE VAGUS NERVE
Psol + ++
Sol ++ ++
SolC ++ ++
SolCe + ++
SolDL ++ ++
SolDM + ++
SolG ++ ++
SolI + ++
SolIM ++ ++
SolM + ++
SolV + ++
SolVL + ++
AP +++ ++
10N ++ ++
OLFACTORY AREAS
AOB ++ ++
AOD + ++
AOE ++ ++
AOL + ++
AOM + ++
AOP + ++
AOV + ++
BAOT ++ ++
DTT + ++
Epl ++ +
E/OV + ++
Gl ++ +
GIA ++ +
GrA + ++
GrO + +
Ipl + +
LOT ++ ++
Mi + +
MiA ++ ++
VTT ++ ++
BASAL GANGLIA
Striatum
Cpu ++ ++
LSS + ++
Nucleus accumbens
Acb + +++
AcbC ++ +++
AcbSh ++ +++
LacbSh ++ +++
Islands of Calleja
Icj ++ ++
IcjM + ++
Olfactory tubercle
(Continued)
TABLE 2 | Continued
Brain nuclei 3413 UBB+1I 3413 UBB+1 D
Tu ++ ++
Globus Pallidus
LGP − −
MGP − −
Subthalamic nucleus
STh + +
NUCLEUS BASALIS OF MEYNERT
NBM + ++
AUDITORY SYSTEM NUCLEI
Inferior colliculus
BIC + ++
CIC + ++
DCIC ++ +++
ECIC + +++
ECIC L1 ++ +++
ECIC L2 ++ +++
ECIC L3 + +++
Medial Geniculate Nucleus
MGD + ++
MGV + +
MGM + +
MZMG + +
Cochlear Nuclei
DC +++ +
GrC − −
VCA + +
VCP − −
Trapezoid nucleus
Tz − −
Superior olive
LSO + +
RAPHE NUCLEI
Cli + +
DR +++ ++
DRC +++ ++
DRD +++ +++
DRI +++ +++
DRV ++ ++
DRVL ++ ++
MnR ++ ++
PMnR ++ ++
PnR ++ ++
RC + ++
Rli − −
RMg +++ ++
Rob + +
Rpa + +
Relative UBB+1 immunoreactivity scores for intensity and density are illustrated in
Figure 2. No UBB+1 immunoreactivity was present in any brain regions in the WT mice.
−, No immunoreactivity; +, low I or D; ++, moderate I or D; +++, high I or D; ++++,
very high I or D.
Frontiers in Neuroanatomy | www.frontiersin.org 6 March 2015 | Volume 9 | Article 26
Gentier et al. Proteasomal inhibition in Alzheimer’s disease
intensity and density in the mouse brain are shown in Figure 2.
Abbreviations of anatomical brain structures are listed in alpha-
betical order in the list of abbrevations and in Table S1. In the
next paragraphs we will discuss first the results of the mouse
line 3413 brain anatomy followed by the results of the human
immunohistochemical study.
Mouse Studies
UBB+1 in the Telencephalon and Diencephalon
The present study extends and provides specific details in fol-
low up to our initial global descriptions of UBB+1 expression in
the forebrain (e.g., cerebral cortex, hippocampus, dentate gyrus,
amygdala, and striatum) and the brainstem in the 3413 tg mice
(Fischer et al., 2009; Irmler et al., 2012) (Figures 1, 2, Table 2).
The CaMKIIα promoter mainly results in strong protein expres-
sion in forebrain areas (Mayford et al., 1996a). In keeping with
this, the expression of UBB+1 protein was strong in the fore-
brain. In addition, after extensive mapping we observed a wide
range of UBB+1 expression in hindbrain regions (e.g., brain-
stem and cerebellum) where other groups also showed the pres-
ence of CamKIIα (Mayford et al., 1996b). The analysis of the
immunohistochemical expression in the mouse brain is aggre-
gated by anatomical region (i.e., telencephalon, diencephalon,
mesencephalon, pons, medulla oblongata, and cerebellum).
Telencephalic structures in the mouse brain
In most of the forebrain regions, the 3413 mice showed low
to very high expression (+;++;+ + +;+ + ++) of UBB+1
(Table 2, Figure 2). In the neocortex, layers (L) 2, 3, 4, 5, and
6 showed a low to moderate intensity with a moderate (L5, L6)
to high (L2, L3, L4) density of UBB+1 cells while UBB+1 was
absent in L1. These data demonstrated that UBB+1 was not
uniformly stained in the classical six layers of the neocortex.
The caudomedial entorhinal cortex (CEnt), retrosplenial granu-
lar cortex (RSGa, b and c) and primary visual cortex (V1) showed
a high UBB+-intensity while the other cortical areas (e.g., APir,
Cg1, Cg2, Pir, CxA, DEn, DP, Ect, FrA, IL, LO, M2, PrL, RSD,
V2MM, VEn, and VO) varied between a low to moderate inten-
sity (Table 2). A moderate density was present in all the cortical
areas except for infralimbic cortex (IL) with a low density and the
CEnt, ectorhinal cortex (Ect) and V1 which showed a high den-
sity of UBB+1 cells. The mediolateral area of the secondary visual
cortex (V2ML) was UBB+1-negative (Table 2).
UBB+1 neuronal immunoreactivity was distributed through-
out the hippocampal region with a variable intensity ranging
frommoderate to high and a high to very high cell-density. How-
ever, the molecular layer of the dentate gyrus (Mol), the stratum
lacunosum-moleculare (Lmol) and the stratum radiatum (Rad)
were UBB+1-negative. The polymorph layer (PoDG) of the den-
tate gyrus showed a moderate UBB+1 intensity and density while
the granular layer (GrDG) was highly UBB+1 positive with a very
high density. (Table 2, Figure 2).
In several amygdala nuclei, a low to moderate intensity and a
moderate density of UBB+1-ir cells was observed. In the ante-
rior cortical amygdaloid nucleus (ACo) little or no UBB+1-
immunoreactivity was observed (Table 2). Other telencephalic
structures are described in the Supplementary Materials.
The neuronal cells in OB and the accessory olfactory bulb
(AOB), both receiving olfactory primary afferents, contain a
noticeable amount of UBB+1 within a moderate number of
positive neurons (Table 2, Figures 1, 2). The OB is subdivided
in certain regions which all showed UBB+1-immunoreactivity.
Specifically, the glomerular layer (Gl) and external plexiform
layer (EPl) of the OB showed a moderate UBB+1-intensity and
a low density. A low intensity and density was present in the
mitral cell layer (Mi), in the internal plexiform layer (IPl) and
in the granule cell layer (GrO) of the OB. The ependymal and
subendymal layer/olfactory ventricle (E/OV) had low intensity
UBB+1-immunoreactivity with a moderate density of positive
neurons. A moderate intensity and density were observed in the
nucleus of the lateral olfactory tract (LOT). In the AOB, themitral
(MiA) and glomerular (GIA) cell layer of the AOB expressed a
moderate UBB+1-intensity while a low intensity was detected in
the granule cell layer (GrA) of the AOB. All subdivisions of the
AOB showed a moderate density. The anterior olfactory area is
subdivided into several anterior olfactory nuclei: dorsal (AOD),
external (AOE), lateral (AOL), medial (AOM), posterior (AOP),
ventral (AOV). The AOE expressed a moderate UBB+1-intensity
while the AOD, AOL, AOM, AOP and AOV showed a low inten-
sity. A moderate density was present for all the different nuclei of
the anterior olfactory area.
The basal ganglia structures in the telencephalon as reported
previously were also immunoreactive for UBB+1. The neostria-
tum [caudate nucleus/putamen (CPu)] showed amoderate inten-
sity and density of UBB+1-ir cells. A specific subpopulation of
large neurons in CPu is very highly stained for UBB+1 while
smaller neurons are rather moderate UBB+1 immunoreactive
(Table 2). In addition to the neostriatum, the nucleus accum-
bens (Acb), the olfactory tubercle (Tu), and the Islands of Calleja
(ICj) showed a moderate to high density of UBB+1 positive cells
(Table 2, Figures 1, 2). The globus pallidus lateralis (LGP) and
medialis (MGP) were UBB+1-negative (Table 2). Another basal
ganglia component, the subthalamic nucleus (STh) located in
diencephalon, showed a low expression for UBB+1. Adjacent to
the basal ganglia, the UBB+1 expression was low in the NBM in
tg line 3413 with a moderate number of positive cells (Table 2).
Diencephalic structures in the mouse brain
A detailed summary of the UBB+1 expression in the diencephalic
structures is given in the Supplementary Materials.
UBB+1 in the Mesencephalon
Mesencephalic structures in the mouse brain
We analyzed the UBB+1 expression in tectal and tegmental
mesencephalic brain regions. The IC contained a clear UBB+1-
immunoreacitiviy. The IC is subdivided into the dorsal cortex
(DCIC) and external cortex (ECIC), the central nucleus (CIC)
and the nucleus of the brachium of the IC (BIC) which showed
staining intensities varying from low to moderate and densi-
ties from moderate to high number of UBB+1-ir cells (Table 2,
Figures 1, 2). The IC is connected with brain structures located in
the diencephalon, pons and medulla oblongata, and which are all
part of the auditory system e.g., medial geniculate nucleus (MG;
diecenphalon), the medullary cochlear nuclei (DC, VC; medulla
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FIGURE 1 | Photomicrographs of UBB+1 distribution in the brain of
UBB+1 tg mice (line 3413) shown in sagittal and coronal sections.
(A) Sagittal overview of UBB+1 staining in a 7-month-old 3413 tg mouse
corresponding to sagittal figure 106 in the mouse brain atlas of Franklin
and Paxinos (2007) with rectangles showing the locations of higher
magnifications in (B–D). (B) OB, (C) Acb and (D) IC. (B) Shows the
presence of UBB+1 in neurons of the OB, accessory olfactory bulb (AOB)
and the anterior olfactory area (AO) at higher magnification. The insert
shows a higher magnification of the AOB. (C) UBB+1 expression in the
Acb. Insert shows higher magnification of UBB+1-positive cells. Filled
triangle shows a cell in which the UBB+1 staining is cytoplasmic and the
nucleus is negative. (D) UBB+1-immunoreactivity in the IC. Insert shows
a higher magnification of the immunoreactive cells in the DCIC. (E)
Coronal section of a 15-month-old 3413 tg mouse showing the presence
of UBB+1 in the dorsal raphe (corresponding to coronal figure 69 in the
mouse brain atlas of Franklin and Paxinos, 2007). (F) shows this region
at a higher magnification. Insert in (F) shows the UBB+1-immunoreactive
cells in the DR. Bars: (A), 1mm; (B,D,F), 200µm, (insert in B,C),
100µm, (E), 500µm, (insert in C, insert in D), 20µm, insert in (F),
50µm. Acb, nucleus accumbens; AOB, accessory olfactory bulb; AO,
anterior olfactory area; Cb, cerebellum; CIC, central nucleus of IC; Cx,
cerebral cortex; DCIC, dorsal cortex of IC; DR, dorsal raphe; EplA,
external plexiform layer of the accessory olfactory bulb, ECIC, external
cortex of IC; GlA, glomerular layer of the accessory olfactory bulb; Hip,
hippocampus; IC, inferior colliculus; LS, lateral septal nucleus; LV, lateral
ventricle; MiA, mitral cell layer of the accessory olfactory bulb; OB,
olfactory bulb; PAG, periaqueductal gray; Sol, nucleus of the tractus
solitarius; Tu, olfactory tubercle.
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FIGURE 2 | Schematic sagittal (A,B) and coronal (C) overviews showing
the mean UBB+1 intensity (blue) (A,C left) and density (green) (B,C
right) in a wide range of mouse brain nuclei. Regions previously reported
to be UBB+1 immunoreactive (cerebral cortex, hippocampus, dentate gyrus,
amygdala, striatum, nucleus parabrachialis, and Sol) are shown in brown. The
UBB+1 intensity and density in OB, Acb, IC and the raphe nuclei are shown in
blue and green, respectively. Different gradations of brown, blue, and green are
used indicating the level of staining intensity or density with a light gradation for
a low intensity or density, a medium gradation for a moderate intensity or
density level, a dark gradation for a high intensity or density level and a very
dark gradation for a very high intensity or density. Other sizeable regions with a
low to moderate UBB+1-immunoreactivity are shown in purple. However,
more regions are positive for UBB+1, for details see Tables 2 and S2. Figures
are adapted from the mouse brain atlas of Franklin and Paxinos figure 106 and
73, respectively (Franklin and Paxinos, 2007). BST, bed nucleus of the stria
terminalis; Gi, gigantocellular reticular nucleus; HTh, hypothalamus; PAG,
periaqueductal gray; PnC, pontine reticular nucleus, caudal part; PnO, pontine
reticular nucleus, oral part; S, septal area; SC, superior colliculus; Th,
thalamus.
oblongata), the pontine superior olive and the pontine trapezoid
nucleus (Tz; pons). The subnuclei of the medial geniculate
nucleus (dorsal, ventral, medial part and the marginal zone)
expressed a low UBB+1 intensity and density (Table 2). The DC
showed a high cell-intensity while the staining in the VC and
superior olive was rather low. No immunoreactiviy was detected
in the Tz (Table 2).
Several raphe subnuclei are also located in themesencephalon:
caudal (Cli) and rostral (Rli) linear nuclei of the raphe, raphe
cap (RC), median (MnR) and paramedian (PMnR) raphe and
all the subnuclei of the dorsal raphe nucleus (DR) namely: cau-
dal part (DRC), dorsal part (DRD), interfascicular part (DRI),
ventral part (DRV), ventrolateral part (DRVL). The RC and Cli
expressed a low UBB+1 staining while the Rli was negative for
UBB+1. Amoderate intensity and density was present in theMnR
and PMnR. The different subnuclei of the dorsal raphe showed
intensities and densities varying from moderate to high (Table 2,
Figures 1, 2).
Additional mesencephalic structures and their immunore-
activity for UBB+1 are summarized in the Supplementary
Materials.
UBB+1 in the Pons, Cerebellum and Medulla
Oblongata
Pons and cerebellum structures in the mouse brain
As outlined in the introduction, previous experiments exam-
ined the presence of UBB+1 in respiratory nuclei (Irmler et al.,
2012). Table 2 and Figure 2 show a high to very high UBB+1-
intensity in the nucleus parabrachialis, a pontine respiratory con-
trol center. Differences were present in medial external (MPBe),
lateral ventral (LPBV), and in lateral internal (LPBI) parabrachial
nucleus which have a moderate intensity, and the waist part
(PBW), with a low intensity of UBB+1-ir cells. The UBB+1 den-
sity in the different parabrachial nuclei varied from moderate to
high. The locus coeruleus (LC) exhibited a similar low to mod-
erate staining intensity (Irmler et al., 2012). The ventral part of
the nucleus subcoeruleus showed a low UBB+1 expression as well
while the dorsal part was negative (Table S2). The staining in the
pontine part of the raphe nuclei (PnR) was moderate for intensity
and density (Table 2, Figure 1). A more detailed overview about
pontine nuclei and the UBB+1-immunoreactivity is given in the
Supplementary Materials.
The cerebellum showed a high expression of UBB+1 in specific
cerebellar regions and will be addressed in a separate study.
Medulla oblongata in the mouse brain
As reported previously, high UBB+1 expression occurred in
brain stem centers namely the nucleus of the solitary tract (Sol),
the area postrema (AP) and the dorsal motor nucleus of the vagus
nerve (10N) (Irmler et al., 2012) (Table 2, Figure 2).
With respect to the medullary raphe nuclei, the raphe obscu-
rus (ROb), and the raphe pallidus (RPa) showed a low UBB+1
staining while the raphe magnus (RMg) showed a high inten-
sity and a moderate density (Table 2). More medullary structures
positive for UBB+1 are described in the SupplementaryMaterials.
Human Studies
UBB+1 in the Human Olfactory Area, Basal Ganglia,
and Nucleus Basalis of Meynert
The olfactory areas analyzed comprised olfactory bulb, olfactory
tract and the cerebral cortical area adjacent to the bulb and tract,
piriform cortex (Pir). In order to investigate whether the distri-
bution of UBB+1-immunoreactivity overlaps with other patho-
logical changes typical of AD, these areas were also mapped
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using antibodies against neuronal markers for pre-tangles, NFTs
and plaques. These immunohistochemical results showed that
AD markers (NFTs and plaques) were present in all AD cases,
but not in the non-demented controls (Table 3, Figures 3, 4). A
clear differential distribution of pathology was detected within
the olfactory system of the Braak 5 cases. The Pir showed high
density of immunoreactive substrates (Figure 4), which progres-
sively decreased in the olfactory tract and the bulb. Specifically,
the olfactory tract expressedmoderate AD-related pathology, and
immunoreactivity was restricted to island in the central portion
of the structure. This region has been identified by Del Tredici
et al. as the anterior olfactory nucleus (AON) (Figure 3) (Del
Tredici et al., 2002). In the OB, either no pathology or very few
reactive substrates were present. The Pir exhibited both Aβ depo-
sition and tau pathology (Figure 4). High densities of plaques,
both neuritic and non-neuritic, were homogeneously distributed
throughout the layers of the Pir. NFTs and NTs were present in
moderate to high densities and showed a fairly consistent laminar
distribution, being concentrated in middle and deep layers.
Staining and analysis were also performed on cryoprotected
olfactory tissue sections (Table 1, Figure 3). In these samples,
the anatomical subdivisions of the human OB were not always
clear to distinguish. In the external part of the bulb, the sec-
tions presented a layer recognizable as the olfactory nerve layer.
Adjacent regions, most likely the glomerular layer, exhibited
rounded structures organized in a line over the surface of the
bulb. More internally, a layer composed of fibers, most likely the
external plexiform layer was distinguishable. In the central por-
tions of these sections, a high number of cells could be visualized.
Presumably, these regions comprised the mitral cell, the inter-
nal plexiform, and the granule cell layers. Immunohistochemi-
cal expression of UBB+1 and AD-specific neuropathology in the
OB and olfactory tract (more specifically the AON) is illustrated
in Figure 3. UBB+1 immunoreactivity was mainly restricted to
central portions of the bulb, external layers exhibiting either no
pathology or few isolated cells and stained threads. All three AD
cases (cryoprotected tissue) expressed low to high density of NTs
and NFTs throughout the layers of the bulb and expressed few
isolated UBB+1-positive cells in the central regions. Only one
case (patient #10) showed Aβ deposition, which was restricted
to the central regions of the bulb namely the granule cell
layer.
With respect to the human basal ganglia including the puta-
men (Pu) and caudate nucleus (Cd) (forming the neostriatum),
globus pallidus (GP) and adjacent regions, such as the Acb and
the NBM. In all AD cases, AD-related pathology (plaques and
NFTs) was present in the basal ganglia (Table 4). The Braak 3
and the four Braak 5 cases exhibited comparable densities of
depositions in the basal ganglia nuclei and in the NBM. The
non-demented controls displayed occasional NFTs and UBB+1-
positive cells in the NBM, whereas the nuclei of the basal gan-
glia of the same cases were not affected. Immunohistochemical
expression of UBB+1 and AD-specific neuropathology in the Acb
and in the NBM is illustrated in Table 4 and in Figures 5, 6.
TABLE 3 | Immunoreactivity for UBB+1, pre-tangle material (MC1), tangles (CP13) and plaques (6F3D) in paraffin and cryostat sections of the human
olfactory system of controls (Braak stage 0), intermediate phase (Braak stage 3) and AD patients (Braak stage 5).
Case Olfactory bulb Olfactory tract Piriform cortex
UBB+1 MC1 CP13 6F3D UBB+1 MC1 CP13 6F3D UBB+1 MC1 CP13 6F3D
BRAAK 0
3 NA NA NA − NA NA NA − − − − −
BRAAK 5
5 − − +* − − +* ++ * − + ++ +++ +++
6 − − − + − +* +* − − ++ ++ +++
8 NA NA NA NA − +* ++ * + + ++ +++ +++
Cryoprotected sections of the olfactory bulb
Case Olfactory nerve layer Glomerular layer External plexiform layer Central regionsa
UBB+1 MC1 CP13 6F3D UBB+1 MC1 CP13 6F3D UBB+1 MC1 CP13 6F3D UBB+1 MC1 CP13 6F3D
BRAAK 0
1 − − − − − − − − − − − − − − − −
BRAAK 3
4 NA NA NA NA NA NA NA NA +* + − − ++ +++ − −
BRAAK 6
9 − − − − + + − − +* + − − ++ +++ − −
10 − NA − − + + + − + NA − − ++ NA + +
Paraffin-embedded tissue of the olfactory bulb, olfactory tract and olfactory cortex.
aPresumably comprises mitral cell, internal plexiform, and granule cell layers.
*Density of immunoreactivity exclusively refers to the occurrence of NTs, the region is devoid of neuronal staining, such as NFTs.
NA, tissue was not available for analysis.
−, No ir; +, low ir; ++ moderate ir or +++ high ir based on densities of NFTs, plaques, and positive neuronal cells.
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There was a differential distribution of AD-related pathology
within several structures. In the putamen, a rostro-caudal gra-
dient could be detected with respect to Aβ deposition, meaning
that rostral portions of the nucleus exhibited a greater density of
FIGURE 3 | Expression of UBB+1 and AD neuropathology (NFTs, NTs
and Aβ) in sections of the human olfactory bulb and tract of patient #10
(Braak 6). (A–D) shows olfactory tissue incubated with antibodies against (A)
UBB+1, (B) pre-tangles (MC1), (C) tangles (CP13), and (D) Aβ plaques.
Asterisk shows intracellular accumulations, represented by neuronal staining
(A) UBB+1 immunoreactivity present in neuronal cells of the OB (asterisk).
(B–C) Presence of misfolded tau in pretangles and NFTs (asterisk). NTs are
shown by the filled triangles. (C) The insert shows the AON of the tract. (D)
Presence of Aβ plaque formation (arrow). Bars: (A–D), 100µm, insert in (C),
500µm. AON, anterior olfactory nucleus.
plaques than caudal portions. Furthermore, NFTs were homoge-
neously distributed in the rostral Pu, whereas the caudal Pu dis-
played higher concentrations of tau pathology in the ventral area
(PuV) and in the regions adjacent to lateral medullary lamina
FIGURE 4 | Photomicrographs of UBB+1 and AD neuropathology
(NFTs, NTs, and Aβ plaques) in the human piriform (Pir) cortex
adjacent to the OB of patient #5 (Braak 5). (A–D) shows the olfactory
tissue incubated with antibodies against (A) UBB+1, (B) pre-tangles (MC1),
(C) tangles (CP13), and (D) Aβ plaques. Asterisk shows intracellular
accumulations, represented by neuronal staining. (A) The presence of
UBB+1 in the neuronal cells (asterisk) of the Pir. (B,C) Pir expresses
misfolded tau in pretangles and NFTs (asterisk). NTs are shown by filled
triangles. (D) Abundant present of Aβ plaque formation (arrow) in the Pir.
Bars: (A–D), 100µm.
TABLE 4 | Immunoreactivity for UBB+1, pre-tangle material (MC1), tangles (CP13), and plaques (6F3D) in vibratome sections of the basal ganglia of
controls (Braak stage 0), intermediate phase (Braak stage 3) and AD patients (Braak stage 5).
Case Nucleus accumbens Striatum (Pu/Cd) Globus pallidus Nucleus basalis of Meynert
UBB+1 MC1 CP13 6F3D UBB+1 MC1 CP13 6F3D UBB+1 MC1 CP13 6F3D UBB+1 MC1 CP13 6F3D
BRAAK 0
2 – – – – – – – – – – – – + + + –
3 – – – – – – – – – – – – + – + –
BRAAK 3
4 − + ++ +++ – – – ++ – – – – – +++ +++ ++
BRAAK 5
5 +* ++ ++ +++ + + + +++ – – – – – +++ +++ +++
6 – – + +++ + + + +++ – – – – ++ ++ +++ +++
7 – – + +++ + + + +++ – – – – NA NA NA NA
8 – – + +++ + + + +++ – – – – ++ ++ +++ +++
NA, tissue was not available for analysis.
−, No ir; + low ir, ++ moderate ir, or +++ high ir based on densities of NFTs, plaques and positive neuronal cells.
*Expression of UBB+1 in the Acb of one patient (#5) which was also affected by tau pathology.
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FIGURE 5 | UBB+1 and AD neuropathology (NFTs, NTs, and Aβ plaques)
in the human basal ganglia. (A) Photomicrograph of a 50µm-thick coronal
section from the Acb of patient #5 (Braak 5). (B) Higher magnification of the
boxed region in (A) incubated with the antibody against UBB+1, (C–E) Higher
magnifications of boxed area in adjacent sections stained for (C) pre-tangles
material (MC1), (D) tangles (CP13) and (E) Aβ plaques. The Acb, together with
other nuclei of the basal ganglia (Cd and Pu), presents little
UBB+1-immunoreactivity (asterisk). Asterisks show neurons with intracellular
accumulations. NTs are shown by filled triangles and Aβ plaques by an arrow.
Bars: (A), 1mm, (B–E), 200µm. Acb, nucleus accumbens, ec, external
capsule; FPu, nucleus accumbens putaminal fundus; ic, internal capsule; LV,
lateral ventricle; OlfA, olfactory area.
(lml), compared to central portions. The Cd expressed a homoge-
neous distribution of plaques, and a concentration of occasional
NFTs adjacent to the internal capsule (ic). Comparable with the
Cd, the Acb displayed homogenous densities of plaques and
occasional NFTs among its subdivisions: subventricular (AcSV),
centromedial (AcCM), medial (AcM), and centrolateral (AcCL)
regions. The caudate fundus (FCd) and putaminal fundus (FPu),
together with Acb part of the ventral striatum, showed plaques
and ocassionally some NFTs. The internal (GPi) and external
(GPe) divisions of the GP exhibited, in a few cases, occasional
NFTs and NTs that were restricted to areas adjacent to the medial
medullary lamina (mml) and the lml. In contrast, central areas of
the nucleus were not affected.
Several structures of the basal ganglia showed selective label-
ing with either amyloid deposition or tau pathology. Acb, Cd,
and Pu expressed severe amyloid pathology, of both the neuritic
and non-neuritic type, but showed only few NFTs and NTs. On
the other hand, the NBM was significantly affected by both amy-
loid depositions and tau pathology. GPe and GPi did not exhibit
plaques, and were only rarely affected by NFTs and NTs.
FIGURE 6 | UBB+1 and AD neuropathology (NFTs, NTs, and Aβ plaques)
in the human NBM. (A) Representative photomicrograph of a 50µm-thick
coronal section from the NBM of patient #4 (Braak 3). (B–E) Higher
magnifications of the boxed region in (A) incubated with four antibodies
against (B) UBB+1, (C) pre-tangles material (MC1), (D) tangles (CP13), and
(E) Aβ plaques. The cholinergic cells of the NBM are shown by an arrowhead.
The nucleus is significantly affected by both tau pathology [neuronal staining
(asterisk) and NTs (filled triangle)] and extracellular Aβ accumulation (arrow).
UBB+1 expression (asterisk) is found in cholinergic cells of the NBM. Bars: (A),
1mm, (B–E), 200µm. ac, anterior commissure; GPi, globus pallidus internal
segment; NBM, nucleus basalis of Meynert.
UBB+1 immunoreactivity was not found in the GP. But the Cd
and Pu did express low densities of UBB+1 in regions also affected
by tau pathology, including FCd, FPu, PuV, and the areas along
lml and ic. UBB+1 was present in low levels in the Acb of only one
Braak 5 patient (#5) which was also affected by tau pathology. The
NBM exhibited a moderate density of immunoreactivity, which
appeared to selectively target cholinergic cells of the nucleus.
The Inferior Colliculus and Raphe Nuclei of the
Human Brain
In the human tissue, plaques, NFTs and UBB+1-immunoreactive
cells were present in the brainstem nuclei of all AD cases (Table 5,
Irmler et al., 2012). These nuclei presented a differential distribu-
tion of pathology among their subdivisions.
In the IC, specifically the CIC was severely affected with
plaques in 100% of AD cases, independent of Braak stage. By
contrast, the DCIC and the ECIC subnuclei were relatively
spared. The inferior colliculi showed selective vulnerability to
Aβ accumulation, expressing a high number of both neuritic
and non-neuritic plaques (Table 5, Figure 7). However, neu-
ronal expression of (pre)-tangles and UBB+1-immunoreactive
substrates was not present in these regions (Table 5, Figure 7).
The human raphe tissue showed that the non-demented con-
trols exhibited either no pathology or few NFTs and NTs and
did not exhibit plaques or UBB+1-positive cells. The Braak 3
patient expressed less pathology than the four Braak 5 patients,
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TABLE 5 | Immunoreactivity for UBB+1, pre-tangle material (MC1), tangles (CP13), and plaques (6F3D) in vibratome sections of the IC and the raphe
nuclei of controls (Braak stage 0), intermediate phase (Braak stage 3) and AD patients (Braak stage 5).
Case Inferior colliculus Dorsal raphe nucleus Median raphe nucleus
UBB+1 MC1 CP13 6F3D UBB+1 MC1 CP13 6F3D UBB+1 MC1 CP13 6F3D
BRAAK 0
2 NA NA NA NA − − − − − − − −
3 − − + − − − + − − − + −
BRAAK 3
4 − + + +++ + ++ +++ + − − + −
BRAAK 5
5 − + + +++ ++ +++ +++ ++ ++ +++ +++ ++
6 − +++* +++* +++ + ++ +++ − + ++ +++ −
7 NA NA NA NA + +++ ++ − ++ ++ +++ −
8 − + + +++ ++ +++ +++ − ++ +++ +++ +
*Immunoreactivity is almost exclusively related to the presence of neuritic plaques; the region expresses only few NFTs.
NA, tissue was not available for analysis.
−, No ir; + low ir, ++ moderate ir, or +++ high ir based on densities of NFTs, plaques and positive neuronal cells.
particularly in the MnR. The MnR and DR express selective
vulnerability to tau pathology, being almost devoid of plaques.
Both MnR and DR were strongly stained by antibodies against
pre-tangles (MC1) and NFTs (CP13) and presented a moderate
number of UBB+1-positive structures.
The subdivisions of the DR, namely dorsal DRD, DRV, DRVL,
and DRI were equally affected by AD-related pathology with a
moderate number of UBB+1 positive structures and high num-
ber of tangles. In the MnR, immunoreactive substrates, such as
NFTs and NTs, were especially concentrated in the medial divi-
sion (mMnR), while the PMnR exhibited AD-related pathology
to a lesser extent (only expressing NTs, but not NFTs). Results are
summarized in Table 5 and Figure 8.
Discussion
The present study describes an extensive topographic mapping
of the distribution of UBB+1 in the brain of 3413 mice using
a sensitive (i.e., ABC technique) immunohistochemical method
(Fischer et al., 2009; Irmler et al., 2012). As a next step, the
significance of UBB+1 and neuropathological markers in five
brain areas in the mouse brain was compared with the distri-
bution in human postmortem AD brain tissue. Currently, it is
not known in either mouse or human whether the distribution
of UBB+1 indicates that UBB+1 affects the phenotype every-
where it is present. However, neuropathological studies provide
possible links with several additional brain regions, AD pheno-
type and/or proteasomal dysfunction as discussed below. This
was already described in our earlier study (Irmler et al., 2012)
for the brainstem region where UBB+1 was found in respi-
ratory centers in the mouse brain which could also be trans-
lated to the human brain. Although the value of transgenic
models must not be overestimated, our anatomical and func-
tional study in the brainstem of line 3413 showed predictive
power for AD (Irmler et al., 2012). Therefore, the presence of
UBB+1 can be a useful indicator in other neurodegenerative dis-
eases as shown recently for ER-associated degradation (ERAD)
dysfunction in familial encephalopathy with neuroserpin inclu-
sion bodies (FENIB) (Schipanski et al., 2014).
In the next paragraphs, we will discuss the staining results in
mouse and human tissue per region, the comparison between
the two species and possible links with other neuropathological
studies.
Olfactory Bulb and Olfactory Cortex
Aging is associated with a decrement in olfactory function, rep-
resented by a progressive decline in the ability to detect, identify,
and discriminate odors (Mobley et al., 2014). Olfactory deficits
have been also described in a variety of neurodegenerative dis-
orders, including AD (Attems et al., 2014). Dysfunction in olfac-
tion is a predictor of the incidence of mild cognitive impairment
(MCI) and of the conversion of MCI to AD (Djordjevic et al.,
2008).
As mentioned above, the UBB+1 tg mouse line 3413 accu-
mulates aberrant ubiquitin in low to moderate densities in the
OB and the AOB. In contrast, in humans the olfactory structure,
which lacks AOB, is relatively spared. Thus, UBB+1 seems not
to be involved in functional impairment of neural cells at lower
levels of the processing pathway. UBB+1-positive cells, how-
ever, were known to accumulate in areas (e.g., hippocampus and
frontal cortex) that are targeted by the neurons of the primary
olfactory cortex (Fischer et al., 2009). Therefore, it can be spec-
ulated that occurrence of UBB+1− positive cells might rather be
implicated in the emergence of symptoms associated with higher-
order processing, such as inability to identify or discriminate
among odors.
Another focus point is the possible association between nora-
drenergic deficiency and olfactory dysfunction in AD. Tg2576
mice showed olfactory dysfunction together with degenera-
tion of noradrenergic neurons in the LC, the main area of
noradrenaline production (Guerin et al., 2009) and projections
to the OB. Additionally, LC degeneration in APP23 tg mice
enhances inflammation, amyloid plaque load, and neuronal cell
death in LC projection regions (e.g., OB) resulting in reduced
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FIGURE 7 | UBB+1 and AD neuropathology (NFTs, NTs, and Aβ plaques)
in the human IC. (A) Representative photomicrograph of a 50µm-thick
coronal section from the brainstem of patient #6 (Braak 5). (B–E) Higher
magnifications of the boxed region in (A) incubated with four antibodies
against (B) UBB+1, (C) pre-tangles material (MC1), (D) tangles (CP13), and
(E) Aβ plaques. The IC show selective vulnerability to Aβ accumulation,
expressing a high number of both neuritic (star) and non-neuritic (arrow)
plaques. Neuronal staining, represented by NFTs and UBB+1-immunoreactive
substrates, is not present in this region. Bars: (A), 1mm, (B–I), 200µm. Aq,
cerebral aqueduct; CIC, central nucleus of IC; DCIC, dorsal cortex of IC; DR,
dorsal raphe nucleus; ECIC, external cortex of IC; IC, inferior colliculus.
neuronal integrity and cognitive performance (Heneka et al.,
2006). Furthermore, it was demonstrated in an ADmouse model
(APPswe, PSEN1dE9) mice that induction of LC degeneration
induced exacerbation of olfactory short term memory deficits, a
decline in olfactory discrimination and an increase in Aβ load
in the granule cell layer of the OB (Rey et al., 2012). The LC is
one of the brainstem nuclei wherein tau pathology is apparent,
prior to the occurrence of cortical β-amyloid pathology (Braak
et al., 2011). Notably, UBB+1-immunoreactivy was also present
in the LC (Irmler et al., 2012). Consequently, UBB+1 accumula-
tion might be involved in the noradrenergic neurodegeneration
in the LC and olfactory dysfunction in AD. Therefore, perform-
ing odor tests with line 3413 would provide valuable information
to the question whether UBB+1 accumulation in OB and LC
is reflected in an impaired olfactory dysfunction. UBB+1 in the
AOB could be associated with and could be tested for social and
reproductive behaviors.
With respect to neuropathology, the present study also inves-
tigated the distribution of amyloid β and tau in the human olfac-
tory bulb, tract and primary olfactory cortex of AD patients
and controls. The human olfactory cortex expressed both NFTs
and Aβ plaques, whereas olfactory bulb and tract more com-
monly exhibit cytoskeletal pathology. Low densities of NFTs and
NTs were found in external layers of the bulb, namely glomeru-
lar and external plexiform layers. Higher densities were instead
detected in central areas comprising mitral cell, internal plexi-
form and granule cell layers. In the olfactory tract immunoreac-
tivity was restricted to the AON. Consistent with the results of the
present study, Braaks group found accumulation of NFTs, NTs,
and plaques in this nucleus (Ohm and Braak, 1987).
In conclusion, the olfactory region is relatively spared in
humans for UBB+1 expression and therefore there is no one to
one relationship between mouse and human for this region. The
present study confirmed the presence of plaques and tangles in
the human olfactory region.
Basal Ganglia
The different subdivisions of the Acb, involved in reward and
reinforcement mechanisms and in regulating emotional behav-
ior (De Jong et al., 2011), showed in the 3413 tg line a high
density of UBB+1 immunoreactive cells and a moderate UBB+1
cell-intensity.
By contrast, in the human brain UBB+1 was present only
in few isolated cells of Acb in a single AD case. In all AD
patients, Acb showed severe Aβ pathology in both neuritic and
non-neuritic plaques, however only a few NFTs and NTs were
present. Comparably, senile plaques were demonstrated in the
ventral striatum of AD patients (Suenaga et al., 1990). A num-
ber of studies have shown dopaminergic (DAergic) dysfunction
in AD patients, mainly in the striatum. As the DAergic brain
reward system is essential to experience motivation and plea-
sure, DAergic dysfunction in AD patients was well-correlated
with apathy defined as a lack of motivation. Apathetic symptoms
are detected in up to 47% of patients with mild AD and up to 80%
in those with severe AD (Mitchell et al., 2011). A reduction in
dopamine uptake was shown in the Acb in AD patients compared
to non-demented controls (Murray et al., 1995).
These data suggest that there is no relation between mouse
and human on UBB+1 expression in the Acb. Apparently, pro-
teasomal malfunctioning seems not to be involved in the DAergic
dysfunction seen in AD.
Additionally to the Acb, the mouse Pu and Cd are more
affected by UBB+1 accumulation compared to the human brain
while the GP was spared of any UBB+1 labeling for both mouse
and human. We also demonstrated that the human Pu and Cd
were severely affected by amyloid deposition and being almost
devoid of cytoskeletal aggregates, whereas GP was relatively
spared of any pathology. This is consistent with previous work
demonstrating diffuse plaques in Cd, Acb, and Pu combined with
an absence of plaques in GP (Brilliant et al., 1997). Taken together,
these data suggest that NFTs, as well as UBB+1, seem not to be
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FIGURE 8 | UBB+1 and AD neuropathology (NFTs, NTs, and Aβ
plaques) in the human raphe nuclei. (A) Photomicrograph of a
50µm-thick section from the brainstem cut perpendicular to the long axis of
the spinal cord of patient #8 (Braak 5). (B–E) Higher magnifications of the
MnR [lower boxed region in (A)] incubated with four antibodies against (B)
UBB+1, (C) pre-tangles material (MC1), (D) tangles (CP13), and (E) Aβ
plaques. (F–I) Larger magnifications of the DR [upper boxed region in (a)]
incubated with the same four antibodies. (F) Ubi2A; (G) MC1; (H) CP13; (I)
6F3D. The raphe nuclei located in the rostral brainstem (MnR and DR) express
selective vulnerability to tau pathology (asterisk, neuronal staining; filled
triangle, NTs), being almost devoid of plaques (arrow). Both MnR and DR are
strongly stained by antibodies directed against pre-tangle material (MC1) and
NFTs (CP13), and present a moderate number of UBB+1-positive substrates
(asterisk). Bars: (A), 1mm, (B–I), 200µm. Aq, cerebral aqueduct; DR, dorsal
raphe nucleus; LC, locus coeruleus; mlf, medal longitudinal fasciculus; MnR,
median raphe nucleus, PnO, pontine reticular nucleus oral part.
involved in the pathological changes that affect this part of the
human basal forebrain. However, we confirmed the presence of
plaques in basal ganglia.
The analysis of the human basal ganglia availed an examina-
tion of structures that lie adjacent to them. The NBM is con-
sidered one of the structures most susceptible to neurofibrillary
degeneration, (Mesulam et al., 2004). Atrophy was shown via
MRI in the NBM of AD patients, most pronounced in the pos-
terior subdivision (Ch4p) as well as a reduction in the number
of Ch4p cholinergic neurons ranging about 70% of age-matched
controls (Jellinger, 2014). The present study demonstrated severe
accumulation of tangle-bearing neurons in the NBM of all
AD cases, independently of disease progression. The occur-
rence of few isolated NFTs could be also detected in brains
of non-demented controls, which is in line with the finding
that cholinergic neurons express neurofibrillary pathology even
during normal aging, but increases significantly in MCI and
worsens in AD (Mesulam, 2013). A clear presence of UBB+1 was
also shown in the human AD cases, which is consistent with a
previous study (Van Leeuwen et al., 2000). The occurrence of
early and severe cytopathology of NBM, together with a profound
reduction of cholinergeric innervation (Whitehouse et al., 1982),
may be partly responsible for the existence of a wide range of
symptoms AD patients commonly suffer from.
Inferior Colliculus
Age-related auditory deficits are quite common in the elderly. AD
patients are known to exhibit structural changes (neuronal loss,
primary sensory deafferentation) in the central auditory path-
ways (Sinha et al., 1993). Central auditory dysfunction (CAD)
includes individuals hearing well in a quiet environment but hav-
ing hearing problems in environments with a lot of background
noise (e.g., competing conversations). Studies demonstrated an
increased risk of AD in individuals with CAD and suggest that
CAD is an early manifestation of AD that occurs before any
sign of cognitive decline. Indeed, people suffering from MCI
showed CAD to a considerable extent (Idrizbegovic et al., 2011).
Thus, auditory dysfunction may not only be a valuable tool for
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diagnosing AD at an early stage, it may also be predictive for the
development of AD. Moreover there is substantial evidence for
neurodegeneration such as senile plaques (Ohm and Braak, 1989)
and neurofibrillary tangles (Dugger et al., 2011) in the medial
geniculate nucleus ventral part (MGV), the CIC, the primary
auditory and auditory association cortices of AD patients.
In the present study, expression of UBB+1 in line 3413 was
found in the IC with a density varying from moderate to high.
By contrast, in the human brain, UBB+1− immunoreactive sub-
strates were not detected in the IC, which is consistent with
the finding that UBB+1 co-localizes with tau pathology, such
as NFTs and dystrophic neurites, but not with amyloid deposi-
tions (Van Leeuwen et al., 1998). In line with other research work
(Parvizi et al., 2001), the human immunohistochemical experi-
ments demonstrated that CIC is severely affected in AD, con-
trary to the external layers of the nucleus (ECIC, DCIC), which
expressed very low densities, if any, of immunoreactive substrates
(plaques or tangles). Furthermore, the IC expressed selective vul-
nerability to amyloid pathology, being almost devoid of NFTs.
One Braak 5 patient (#6) showed a high immunoreactivity for
(pre)-tangles, however it is related to its presence in neuritic
plaques.
In conclusion, our experiments demonstrated that high con-
centrations of AD-related pathology (i.e., MC1, CP13, and Aβ)
affect the inferior colliculi, especially the CIC, in humans. Fur-
thermore, because the Braak 3 case already exhibits severely amy-
loid depositions, it can be claimed that pathological changes in
the nuclei may initiate early in disease’s progression. The involve-
ment of the IC, represented by accumulation of plaques, as well as
neuronal loss and altered dendrite arborization (Baloyannis et al.,
2009), might, therefore, be partly responsible for central auditory
symptoms commonly diagnosed in AD patients.
Raphe Nuclei
Depression is a common comorbidity in individuals with AD and
may also precede the clinical symptoms of AD by several years
(Sierksma et al., 2010). However, it is unclear whether depres-
sion is a risk factor (Geerlings et al., 2008) or a prodromal sign
(Wilson et al., 2004) for dementia and AD. One of the possi-
ble explanations about the pathophysiology of depression is the
“monoaminergic hypothesis” in which a depletion inmonoamine
levels in the brain i.e., serotonin (5-HT) and noradrenaline (NA)
is thought to play a role (Sierksma et al., 2010).
Our human data demonstrated that both DR and MnR accu-
mulate UBB+1− positive cells. These results are in line with
the finding that aberrant ubiquitin is expressed in comparable
brain regions of the 3413 tg mouse. UBB+1-ir cells showed a
low to moderate density of labeling in certain raphe subnu-
clei of the 3413 tg mice. Intriguingly, the DR receives afferents
from the LC. Noradrenergic as well as serotonergic degeneration
of the LC is associated with depression (Ressler and Nemeroff,
2000). It was shown in tg mice that LC degeneration caus-
ing NA deficiency in AD contributes to early cognitive deficits
(Hammerschmidt et al., 2013). As UBB+1-ir cells were shown
in both the DR and LC of 3413 tg mice, it is possible that
UBB+1 accumulation is associated with depression in AD. These
results show that there is a correlation with UBB+1 expression
in the DR and the MnR in line 3413. Because accumulation of
UBB+1 inhibits proteasomal activity (Van Tijn et al., 2007) and
because its occurrence in other brain regions is associated with
neuropsychological (Fischer et al., 2009) and behavioral (Irmler
et al., 2012) phenotypes, it is likely that the presence of UBB+1-
positive cells in the raphe nuclei contribute to the abnormal func-
tioning of the 5-HTergic system in AD, as well as to the affective
symptoms commonly diagnosed in AD patients.
Additionally, the human data showed that nuclei of the ros-
tral raphe complex, namely DR and MnR are severely affected by
NFTs. The caudal raphe complex (RMg, RPa, ROb) was not ana-
lyzed, but several studies have already shown that such nuclei are
relatively spared in AD (Rub et al., 2000). Consistent with other
work (Parvizi et al., 2001), we demonstrated that the DR and
MnR are selectively vulnerable to cytoskeletal pathology, being
almost devoid of plaques. In addition, it was found that AD-
related pathology in the raphe complex correlates with disease
progression (Rub et al., 2000). The DR manifests lesions at early
stages (Braak 1-2), whereas MnR initiates to show pathology later
(Braak 3-4). Congruently, the Braak 3 patient analyzed in the
present study showed NFTs in DR, but not in MnR. It has been
proposed, that neuropathological changes, such as the aggre-
gation of hyperphosphorylated tau, begin in the raphe nuclei,
subsequently spreading to the transentorhinal cortex apparently
via seeding (Grinberg et al., 2009; Jucker and Walker, 2011).
Accordingly, 20% of Braak 0 cases and 100% of Braak ≥ 1
expressed NFTs in the DR (Grinberg et al., 2009). Our findings
are consistent with this hypothesis.
Concluding Remarks
The present study expands prior work and shows the global
UBB+1 distribution in the brain of the tg mouse line 3413.
We selected five regions, namely the OB, Acb, NBM, IC, and
raphe nuclei. The results support the idea that AD is a phe-
nomenon that involves more than forebrain degeneration asso-
ciated with memory problems. It has been shown that the 3413
tg model has some predictive value, as also noted previously
(Irmler et al., 2012). However, because it is a genetic model
that is useful to address loss of protein control, it has limita-
tions with respect to AD which is a multifactorial disease. Line
3413 can be used as a read-out possibility for further AD-related
research in mice especially when crossed with existing AD lines
and other diseases models to show the relevance of other pro-
cesses such as Aβ plaque formation (Van Tijn et al., 2012) and
other cytological processes (Schipanski et al., 2014). The present
study showed that immunoreactivity for UBB+1 found in the tg
mouse model 3413 is not completely mirrored in the AD brain.
More specifically, we demonstrated in addition to the brain stem
nuclei that areas that present substantial accumulation of tangle
bearing neurons, such as NBM and raphei nuclei, present also
high densities of UBB+1-positive cells. These data can be used
to reveal the impact of proteasomal stress on functioning and
on neurodegenerative pathology as shown by GWAS studies in
AD (International Genomics of Alzheimer’s Disease Consortium
(IGAP), 2015) and to uncover new avenues for research not only
on AD but also on other multifactorial tauopathies (Fischer et al.,
2003) and polyglutamine diseases (such as HD, De Pril et al.,
2004).
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Abbreviations
10N Dorsal motor nucleus of vagus
AAD Anterior amygdaloid area, dorsal part
AAV Anterior amygdaloid area, ventral part
Ac Nucleus of the anterior commissure
Acb Accumbens nucleus
AcbC Accumbens nucleus, core
AcbSh Accumbens nucleus, shell
AcCL Subventricular part of n. accumbens
AcCM Centromedial part of n. accumbens
AcM Medial part of n. accumbens
Aco Anterior cortical amygdaloid nucleus
AcSV Centrolateral part of n. accumbens
Ahi Amygdalohippocampal area
AhiAL Amygdalohippocampal area, anterolateral part
AhiPM Amygdalohippocampal area, posteromedial part
AOB Accessory olfactory bulb
AOD Anterior olfactory area, dorsal part
AOE Anterior olfactory area, external part
AOL Anterior olfactory area, lateral part
AOM Anterior olfactory area, medial part
AON Anterior olfactory nucleus
AOP Anterior olfactory area, posterior part
AOV Anterior olfactory area, ventral part
AP Area postrema
Apir Amygdalopiriform transition area
Aq Cerebral aqueduct
Astr Amygdalostriatal transition area
BAOT Bed nucleus of the accessory olfactory tract
BIC Nucleus of the brachium of the inferior colliculus
BLA Basolateral amygdaloid nucleus, anterior part
BLP Basolateral amygdaloid nucleus, posterior part
BLV Basolateral amygdaloid nucleus, ventral part
BMA Basomedial amygdaloid nucleus, anterior part
BMP Basomedial amygdaloid nucleus, posterior part
BST Bed nucleus of the stria terminalis
CA1 Cornu ammonis 1 (CA1) of hippocampus
CA2 Cornu ammonis 2 (CA2) of hippocampus
CA3 Cornu ammonis 3 (CA3) of hippocampus
Cb Cerebellum
Cd Caudate nucleus
CeC Central amygdaloid nucleus, capsular part
CeL Central amygdaloid nucleus, lateral division
CeM Central amygdaloid nucleus, medial division
CeMAD Central amygdaloid nucleus, medial division, anterodorsal part
CeMAV Central amygdaloid nucleus, medial division, anteroventral part
CeMPV Central amygdaloid nucleus, medial posteroventral part
CEnt Caudomedial entothinal cortex
Cg1 Cingulate cortex, area 1
Cg2 Cingulate cortex, area 2
(Continued)
Continued
CIC Central nucleus of the inferior colliculus
Cli Caudal linear nucleus of the raphe
CPu Caudate putamen (striatum)
Cx Cerebral cortex
CxA Cortex-amygdala transition zone
DC Dorsal cochlear nucleus
DCIC Dorsal cortex of the inferior colliculus
Den Dorsal endopiriform nucleus
DP Dorsal peduncular cortex
DR Dorsal raphe nucleus
DRC Dorsal raphe nucleus, caudal part
DRD Dorsal raphe nucleus, dorsal part
DRI Dorsal raphe nucleus, interfascicular part
DRV Dorsal raphe nucleus, ventral part
DRVL Dorsal raphe nucleus, ventrolateral part
DTT Dorsal tenia tecta
Ec External capsule
ECIC External cortex of the inferior colliculus
Ect Ectorhinal cortex
E/OV Ependymal and subendymal layer/olfactory ventricle
Epl External plexiform layer of the olfactory bulb
EplA External plexiform layer of the accessory olfactory bulb
FC Fasciola cinereum
FCd Nucleus accumbens, caudate fundus
Fpu Nucleus accumbens, putaminal fundus
FrA Frontal association cortex
Gi Gigantocellular reticular nucleus
Gl Glomerular layer of the olfactory bulb
GlA Glomerular layer of the accessory olfactory bulb
GP Globus pallidus
Gpe Globus pallidus, external segment
Gpi Globus pallidus, internal segment
GrA Granule cell layer of the accessory olfactory bulb
GrC Granular layer of the cochlear nuclei
GrDG Granular layer of the dentate gyrus
GrO Granular cell layer of the olfactory bulb
Hip Hippocampus
HTh Hypothalamus
I Intercalated nuclei of the amygdala
Ic Internal capsule
IC Inferior colliculus
ICj Islands of Calleja
ICjM Islands of Calleja, major island
Ig Indusium griseum
IL Infralimbic cortex
IM Intercalated amygdaloid nucleus, main part
IPl Internal plexiform layer of the olfactory bulb
L1 Cortical layer 1
L2 Cortical layer 2
L3 Cortical layer 3
L4 Cortical layer 4
L5a Cortical layer 5a
(Continued)
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Continued
L5b Cortical layer 5b
L6 Cortical layer 6
La Lateral amygdaloid nucleus
LAcbSh Lateral accumbens shell
LaDL Lateral amygdaloid nucleus, dorsolateral part
LaVL Lateral amygdaloid nucleus, ventromedial part
LaVM Lateral amygdaloid nucleus, ventromedial part
LC Locus coeruleus
LGP Lateral globus pallidus
lml Lateral medullary lamina
LMol Lacunosum moleculare layer of the hippocampus
LO Lateral orbital cortex
LOT Nucleus of the lateral olfactory tract
LPB Lateral parabrachial nucleus
LPBC Lateral parabrachial nucleus, central part
LPBD Lateral parabrachial nucleus, dorsal part
LPBE Lateral parabrachial nucleus, external part
LPBI Lateral parabrachial nucleus, internal part
LPBV Lateral parabrachial nucleus, ventral part
LS Lateral septal nucleus
LSO Lateral superior olive
LSS Lateral stripe of the striatum
LV Lateral ventricle
M2 Secondary motor cortex
MeA Medial amygdaloid nucleus, anterior part
MeAD Medial amygdaloid nucleus, anterior dorsal part
MeAV Medial amygdaloid nucleus, anteroventral part
MePD Medial amygdaloid nucleus, posterodorsal part
MePV Medial amygdaloid nucleus, posteroventral part
MG Medial geniculate nucleus
MGD Medial geniculate nucleus, dorsal part
MGM Medial geniculate nucleus, medial part
MGP Medial globus pallidus
MGV Medial geniculate nucleus, ventral part
Mi Mitral cell layer of the olfactory bulb
MiA Mitral cell layer of the accessory olfactory bulb
Mlf Medial longitudinal fasciculus
Mml Medial medullary lamina
mMnR Median raphe nucleus, medial part
MnR Median raphe nucleus
Mol Molecular layer of the dendate gyrus
MPB Medial parabrachial nucleus
MPBe Medial parabrachial nucleus external part
MZMG Marginal zone of the medial geniculate
NBM Nucleus basalis of Meynert
NCS Nucleus centralis superior
OB Olfactory bulb
OlfA Olfactory area
(Continued)
Continued
PAG Periaqueductal gray
PaS Parasubiculum
PBW Parabrachial nucleus waist part
Pir Piriform cortex
PLCo Posterolateral cortical amygdaloid nucleus (C2)
PMCo Posteromedial cortical amygdaloid nucleus (C3)
PMnR Paramedian raphe nucleus
PnC Pontine reticular nucleus, caudal part
PnO Pontine reticular nucleus, oral part
PnR Pontine raphe nucleus
PoDG Polymorph layer of the dentate gyrus
PrL Prelimbic cortex
PrS Presubiculum
PSol Parasolitary nucleus
Pu Putamen
PuV Ventral area of putamen
Py Pyramidal cell layer of the hippocampus
Rad Stratum radiatum of the hippocampus
RC Raphe cap
RLi Rostral linear nucleus of the raphe
RMg Raphe magnus nucleus
ROb Raphe obscurus nucleus
RPa Raphe pallidus nucleus
RSD Retrosplenial dysgranular cortex
RSGa Retrosplenial granular cortex, a part
RSGb Retrosplenial granular cortex, b part
RSGc Retrosplenial granular cortex, c part
S Septal area
Sb Subiculum
SC Superior colliculus
Shi Septohippocampal nucleus
SLEA Sublenticular extended amygdala
SLEAC Sublenticular extended amygdala, central part
SLEAM Sublenticular extended amygdala, medial part
Slu Stratum lucidum, hippocampus
Sol Nucleus of the solitary tract
Sol Solitary tract
SolC Nucleus of the solitary tract, commissural part
SolCe Nucleus of the solitary tract, central part
SolDL Nucleus of the solitary tract, dorsolateral part
SolDM Nucleus of the solitary tract, dorsomedial part
SolG Nucleus of the solitary tract, gelatinous part
SolI Nucleus of the solitary tract, interstitial part
SolIM Nucleus of the solitary tract, intermediate part
SolM Nucleus of the solitary tract, medial part
SolV Nucleus of the solitary tract, ventral part
SolVL Nucleus of the solitary tract, ventrolateral part
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Continued
STh Subthalamic nucleus
Th Thalamus
Tu Olfactory tubercle
Tz Nucleus of the trapezoid body
V1 Primary visual cortex
V2ML Secondary visual cortex, mediolateral area
(Continued)
Continued
V2MM Secondary visual cortex, mediomedial area
VC Ventral cochlear nucleus
VCA Ventral cochlear nucleus, anterior part
VCP Ventral cochlear nucleus, posterior part
VEn Ventral endopiriform nucleus
VO Ventral orbital cortex
VTT Ventral tenia tecta
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